NANobutoshi Ando

Nobutoshi Ando

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nobutoshi Ando has a total of 107 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Variations in survival and perioperative complications between hospitals based on data from two phase III clinical trials for oesophageal cancer

    by K. Kataoka, K. Nakamura, J. Mizusawa, H. Fukuda, H. Igaki, S. Ozawa, K. Hayashi, K. Kato, Y. Kitagawa, N. Ando

    Background: Variations in institutional practice may contribute to different outcomes of cancer treatment. The impact of interinstitutional heterogeneity on outcomes between hospitals after oesophagectomy has not been examined previously using data from surgical clinical trials. Methods: The data from two phase III trials for oesophageal cancer were used. Japan Clinical Oncology Group (JCOG) 9204 involved oesophagectomy (92-OP) versus oesophagectomy plus postoperative chemotherapy (92-POST), with accrual from 1992 to 1997. JCOG9907 involved postoperative chemotherapy (99-POST) versus preoperative chemotherapy (99-PRE), with accrual from 2000 to 2006. Hospitals contributing fewer than three patients were excluded. The influence of time and preoperative chemotherapy on interinstitutional heterogeneity related to postoperative complications and 5-year overall survival were evaluated by comparisons within and between these trial groups. Heterogeneity was estimated by a mixed-effects model after adjusting for age, sex, performance status, location of the primary tumour and clinical stage. Results: Twelve hospitals in 92-OP (114 patients), 13 in 92-POST (114), 19 in 99-POST (158) and 18 in 99-PRE (154) were eligible. There was considerable heterogeneity in predicted postoperative complications in both groups in JCOG9204 (median 31·3 (range 15·0–68·2) per cent), and in 99-PRE (35·2 (22·6–46·6) per cent) but not in 99-POST (27·7 (27·7–27·7) per cent) from JCOG9907. A similar pattern was seen for predicted overall survival (92-POST: 66·4 (range 64·1–68·9) per cent; 99-PRE: 55·9 (54·0–59·7) per cent; 99-POST: 44·4 (44·4–44·4) per cent). Conclusion: Interinstitutional heterogeneity regarding complications and survival after oesophagectomy is a problem that merits wider consideration.


  • Top Cited Papers

    A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907)

    by Nobutoshi Ando, Hoichi Kato, Hiroyasu Igaki, Masayuki Shinoda, Soji Ozawa, Hideaki Shimizu, Tsutomu Nakamura, Hiroshi Yabusaki, Norio Aoyama, Akira Kurita, et al.

    Patients with esophageal carcinoma receiving postoperative chemotherapy showed superior disease-free survival than those receiving surgery alone in a Japan Clinical Oncology Group trial (JCOG9204). The purpose of this study was to evaluate optimal perioperative timing—that is, before or after surgery—for providing chemotherapy in patients with locally advanced esophageal squamous cell carcinoma. Eligible patients with clinical stage II or III, excluding T4, squamous cell carcinoma were randomized to undergo surgery followed (group 1) or preceded (group 2) by chemotherapy consisting of two courses of cisplatin plus 5-fluorouracil. The primary end point was progression-free survival. We randomized 330 patients, with 166 assigned to group 1 and 164 to group 2, between May 2000 and May 2006. The planned interim analysis was conducted after completion of patient accrual. Progression-free survival did not reach the stopping boundary, but overall survival in group 2 was superior to that of group 1 (P = 0.01). Therefore, the Data and Safety Monitoring Committee recommended early publication. Updated analyses showed the 5-year overall survival to be 43% in group 1 and 55% in group 2 (hazard ratio 0.73, 95% confidence interval 0.54–0.99, P = 0.04), where the median follow-up of censored patients was 61.6 months. Concerning operative morbidity, renal dysfunction after surgery in group 2 was slightly higher than in group 1. Preoperative chemotherapy with cisplatin plus 5-fluorouracil can be regarded as standard treatment for patients with stage II/III squamous cell carcinoma.


  • Online First publication from Volume 8, Number 1, 2011

    by Nobutoshi Ando, Springer

  • A multicenter randomized phase II (rPII)/III study comparing concurrent chemoradiotherapy (CRT) with low-dose cisplatin plus continuous infusion of 5-fluorouracil (LDPF) and standard-dose PF (SDPF) for locally advanced unresectable squamous cell carcinoma of the thoracic esophagus (JCOG0303).

    by M. Shinoda, N. Ando, H. Kato, Y. Tsubosa, K. Minashi, G. Watanabe, K. Ikeda, T. Kawano, K. Nakamura, H. Fukuda

    4053 Background: Cisplatin-based CRT is one of the standard treatments for locally advanced unresectable esophageal carcinomas. Although both cisplatin and 5-FU are known to enhance the efficacy of radiotherapy, the optimal chemotherapy regimen has not been established. Thus, we evaluated CRT with LDPF on effectiveness and adverse events for locally advanced unresectable esophageal carcinomas in a randomized study to determine if it is an acceptable alternative to SDPF. Methods: Eligibility criteria included histologically proven squamous cell, adenosquamous, or basaloid carcinoma; tumor located in thoracic esophagus; and definite T4 and/or unresectable regional lymph node metastasis. In arm A, two courses of standard chemotherapy of cisplatin (70 mg/m2, div day1, 29) plus 5-FU (700 mg/ m2, ci day1-4, 29-32) were given with external beam radiation (EBRT) in 30 daily fractions, 5 d/week to a total dose of 60 Gy. In arm B, low dose daily cisplatin (4 mg/ m2, div) plus 5-FU (200 mg/ m2, ci) was administered on the same days that EBRT was given. The primary endpoint was overall survival (OS). The rPII study was designed to evaluate the efficacy of LDPF to decide whether it warranted a phase III trial. Results: Between Apr. 2004 and Jun. 2009, 135 pts (Arm A/B; 67/68) from 40 institutions were randomized. Tumor depth (T1-3/T4) was 18/49 in arm A and 13/55 in arm B. The median follow-up time for all eligible pts was 9.9 mos. Toxicities were almost equivalent in both arms; however LDPF necessitated long hospitalization. Moreover, the OS of pts of LDPF group was slightly inferior to that of those treated with SDPF (hazard ratio, 1.048, 95%CI, 0.782-1.045; median OS (A/B), 13.0/13.6 mos.; 3-year OS (A/B), 30/26%). Because of the inferior efficacy of LDPF, the Data and Safety Monitoring Committee of the JCOG recommended the termination of the study at the end of rPII. Conclusions: CRT with LDPF is not recommended for pts with locally advanced unresectable esophageal cancer. No significant financial relationships to disclose.


  • A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus (JCOG 9907)

    by H. Igaki, H. Kato, N. Ando, M. Shinoda, H. Shimizu, T. Nakamura, S. Ozawa, H. Yabusaki, N. Aoyama, A. Kurita, et al.

    4510 Background: The phase III trial (JCOG9204) comparing postoperative adjuvant chemotherapy using cisplatin plus 5- fluorouracil (5-FU) with surgery alone showed superior disease-free survival in postoperative chemotherapy for patients (pts) with esophageal squamous cell carcinoma (ESCC) (Ando N, et al, J Clin Oncol 2003). This phase III trial was conducted to determine the optimal timing for giving chemotherapy. Methods: Pts with c-stage II, III (excluding T4) ESCC were randomized. In arm A, two courses of chemotherapy with cisplatin (80 mg/m2, div day1) plus 5-FU (800 mg/m2, ci day1–5) were given following surgery of transthoracic esophagectomy with lymphadenectomy. In arm B, two courses of chemotherapy same as arm A were given before surgery. Minimization method was used to balance nodal status (cN0/cN1) and institution. Primary endpoint was progression-free survival (PFS). Secondary endpoints were overall survival (OS), % complete resection, adverse events and surgical complications. Sample size was 330 pts to detect about 13% improvement in 5y-PFS with one-sided alpha 0.05 and power 0.80. Results: Between May 2000 and May 2006, 330 pts (A/B; 166/164, cN0/N1; 114/216) from 24 institutions were randomized. Median age was 61/61 years. No remarkable difference was seen in toxicity and complications between the arms. One treatment-related death was seen in each arm. The planned second interim analysis after completion of accrual was carried out in Mar 2007. Hazard ratio (HR) of PFS was 0.76 (favor in arm B, one-sided stratified logrank p = 0.044) which did not meet the prespecified stopping criteria (p < 0.0254; O’Brien & Fleming alpha spending function), however, arm B was highly superior in overall survival (OS) (HR 0.64, 95%CI: 0.45–0.91, two-sided p = 0.014). Data and Safety Monitoring Committee recommended the early publication. In updated analyses in Aug 2007, median PFS was 2.0 y in arm A, and 2.9 y in arm B, median OS was 2.9 y in arm A and was not reached in arm B. Conclusions: Preoperative chemotherapy with cisplatin plus 5-FU followed by surgery can be regarded as a new standard treatment for stage II/III ESCC. No significant financial relationships to disclose.


  • Top Cited Papers

    Surgery Plus Chemotherapy Compared With Surgery Alone for Localized Squamous Cell Carcinoma of the Thoracic Esophagus: A Japan Clinical Oncology Group Study—JCOG9204

    by Nobutoshi Ando, Toshifumi Iizuka, Hiroko Ide, Kaoru Ishida, Masayuki Shinoda, Tadashi Nishimaki, Wataru Takiyama, Hiroshi Watanabe, Kaichi Isono, Norio Aoyama, et al.

    Purpose: We performed a multicenter randomized controlled trial to determine whether postoperative adjuvant chemotherapy improves outcome in patients with esophageal squamous cell carcinoma undergoing radical surgery. Patients and Methods: Patients undergoing transthoracic esophagectomy with lymphadenectomy between July 1992 and January 1997 at 17 institutions were randomly assigned to receive surgery alone or surgery plus chemotherapy including two courses of cisplatin (80 mg/m2 of body-surface area Ă— 1 day) and fluorouracil (800 mg/m2 Ă— 5 days) within 2 months after surgery. Adaptive stratification factors were institution and lymph node status (pN0 versus pN1). The primary end point was disease-free survival. Results: Of the 242 patients, 122 were assigned to surgery alone, and 120 to surgery plus chemotherapy. In the surgery plus chemotherapy group, 91 patients (75%) received both full courses of chemotherapy; grade 3 or 4 hematologic or nonhematologic toxicities were limited. The 5-year disease-free survival rate was 45% with surgery alone, and 55% with surgery plus chemotherapy (one-sided log-rank, P = .037). The 5-year overall survival rate was 52% and 61%, respectively (P = .13). Risk reduction by postoperative chemotherapy was remarkable in the subgroup with lymph node metastasis. Conclusion: Postoperative adjuvant chemotherapy with cisplatin and fluorouracil is better able to prevent relapse in patients with esophageal cancer than surgery alone.


    • 1 October 2001
      • Vol. 8, 86S-89S

    Laparoscopic detection of sentinel lymph nodes in gastrointestinal cancer: a novel and minimally invasive approach.

    by Y Kitagawa, M Ohgami, H Fujii, M Mukai, T Kubota, N Ando, M Watanabe, Y Otani, S Ozawa, H Hasegawa, et al.

    Although the sentinel node (SN) concept has been validated in malignant melanoma and breast cancer, the application of this concept for other solid tumors, including gastrointestinal (GI) cancer, is still controversial. We have demonstrated the feasibility of radioguided SN mapping during laparotomy in patients with esophageal, gastric, and colorectal cancers. In 188 patients, the SNs identified by this technique had an overall diagnostic accuracy of 96% for regional lymph node metastasis. Aberrant drainage sites that have been called skip metastasis from the primary lesion were detectable using this method. More recently, we have undertaken SN mapping during laparoscopic surgery. A combination of radiotracer and blue dye optimized the identification of SNs that drained GI cancers. Our preliminary data indicate that laparoscopic mapping of the SN is a sensitive intraoperative technique for identifying lymph node micrometastasis, and we believe that it will become an important component of a minimally invasive approach to early-stage GI cancers.


    • 1 June 2001
      • Vol. 102  (6) , 477-83

    [Appropriate extent of lymphadenectomy in esophageal cancer].

    by Y Kitagawa, N Ando, S Ozawa, M Kitajima

    Because of the high frequency and widespread distribution of lymph node metastasis in esophageal cancer, three-field dissection was introduced in the early 1980s. Although improvement in the long-term survival rate of patients who undergo three-field dissection has been reported, the clinical significance of cervical lymphadenectomy is still controversial because the effect of improved upper-mediastinal lymphadenectomy in these patients cannot be excluded. Recently, the sentinel node (SN) concept has been validated in gastrointestinal cancers including esophageal cancer using the radio-guided method. Aberrant drainage routes from the primary lesion have frequently been observed in esophageal cancer and are detectable by radio-guided SN mapping. SN navigation is useful to identify SNs as the functional first basin to evaluate the regional lymph node status and to determine the indications for extensive lymphadenectomy in patients with esophageal cancer. Individualized surgical management of patients with esophageal cancer is essential to improve the quality of life of patients and long-term results.